Novavax (NASDAQ:NVAX) – Equities research analysts at B. Riley lifted their Q2 2018 EPS estimates for Novavax in a research report issued to clients and investors on Wednesday, May 16th. B. Riley analyst G. Zavoico now expects that the biopharmaceutical company will earn ($0.11) per share for the quarter, up from their previous estimate of ($0.15). B. Riley currently has a “Buy” rating on the stock. B. Riley also issued estimates for Novavax’s Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.11) EPS, FY2018 earnings at ($0.45) EPS, Q1 2019 earnings at ($0.13) EPS, Q2 2019 earnings at ($0.13) EPS, Q3 2019 earnings at ($0.13) EPS, Q4 2019 earnings at ($0.13) EPS, FY2019 earnings at ($0.51) EPS and FY2020 earnings at ($0.23) EPS.
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Novavax from a “buy” rating to a “hold” rating in a research report on Thursday, March 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price objective on shares of Novavax in a research report on Thursday, March 15th. BidaskClub raised shares of Novavax from a “hold” rating to a “buy” rating in a research report on Thursday, March 15th. Chardan Capital reaffirmed a “hold” rating on shares of Novavax in a research report on Thursday, March 1st. Finally, ValuEngine raised shares of Novavax from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $3.37.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The company had revenue of $9.70 million for the quarter, compared to analyst estimates of $9.33 million. During the same period in the previous year, the company posted ($0.16) earnings per share. The firm’s revenue was up 70.2% on a year-over-year basis.
In other news, SVP John Trizzino bought 50,000 shares of Novavax stock in a transaction on Monday, May 14th. The stock was purchased at an average cost of $1.64 per share, with a total value of $82,000.00. Following the purchase, the senior vice president now directly owns 138,965 shares of the company’s stock, valued at approximately $227,902.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Stanley C. Erck bought 100,000 shares of Novavax stock in a transaction on Monday, May 14th. The shares were purchased at an average cost of $1.65 per share, with a total value of $165,000.00. Following the completion of the purchase, the insider now directly owns 328,279 shares in the company, valued at $541,660.35. The disclosure for this purchase can be found here. Insiders own 4.00% of the company’s stock.
Large investors have recently modified their holdings of the company. Wells Fargo & Company MN lifted its stake in shares of Novavax by 30.8% in the 3rd quarter. Wells Fargo & Company MN now owns 446,831 shares of the biopharmaceutical company’s stock worth $509,000 after acquiring an additional 105,117 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Novavax by 6.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,225,018 shares of the biopharmaceutical company’s stock worth $1,397,000 after acquiring an additional 71,047 shares during the period. Virtus Fund Advisers LLC acquired a new stake in shares of Novavax in the 4th quarter worth approximately $329,000. Virtu Financial LLC lifted its stake in shares of Novavax by 11,061.4% in the 4th quarter. Virtu Financial LLC now owns 1,124,842 shares of the biopharmaceutical company’s stock worth $1,395,000 after acquiring an additional 1,114,764 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in shares of Novavax in the 4th quarter worth approximately $215,000. 33.41% of the stock is owned by institutional investors.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.